Device Trial Radar · NCT07821112
Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Oct 2027
Study completion Oct 2029
Sponsor
- Lead sponsor
- University of California, IrvineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GT Medical Technologies, Inc.
- First posted
- Sep 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.
Conditions
- Glioma
- Glioblastoma
- GBM
- Glioma, Malignant
- Astrocytoma
- Oligodendroglioma
- Elderly Glioblastoma
- Elderly GBM
Interventions
GammaTile®Device
GammaTile is a bioabsorbable collagen tile embedded with cesium-131 radioactive seeds.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants who were able to receive the GammaTile ImplantTime frame: 28 days
- Number of Participants with Treatment-related Adverse EventsTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.